Tradestie Institutional Equity Comparison Engine

MBIO vs PTN โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

PTN Overall Edge

PTN Captures Institutional Edge (2โ€“1 Pillars ยท 3โ€“6 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Palatin Technologies, Inc. (PTN) driven by superior Valuation, Momentum & Technical while MBIO counters with relative strength in Growth & Margin. Fundamentally, MBIO trades at N/M Forward P/E with 0.0% operating margin (+0.0% YoY revenue) versus PTN at 42.9x Forward P/E and -65.7% operating margin (-80.1% YoY). In options structure, MBIO sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro) against PTN sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro).

Valuation Winner PTN
MBIO N/M vs PTN 42.9x Fwd P/E
Growth & Margin Winner MBIO
Op Margin 0.0% vs -65.7% ยท YoY +0.0% vs -80.1%
Momentum & Technical Winner PTN
1Y -67.4% vs -43.3% ยท 52W Pos 4% vs 6%
Options & Structure Winner Tie
UNCLASSIFIED (N/A IV) vs UNCLASSIFIED (N/A IV)
MBIO NASDAQ
Mustang Bio, Inc.
Pharmaceutical Preparations
$0.39
-6.34% 1D
Market Cap $3.2M
1M Return +4.86%
1Y Return -67.38%
Forward P/E N/M
Unified AI Score
42.9 / 100 HOLD
Tech 40.0 Fund 49.0 Flow 50.0 Mom 70.0
PTN US Equity
Palatin Technologies, Inc.
Pharmaceutical Preparations
$6.12
-1.69% 1D
Market Cap $11.1M
1M Return +1.74%
1Y Return -43.29%
Forward P/E 42.9x
Unified AI Score
31.5 / 100 SELL
Tech 15.0 Fund 30.0 Flow 50.0 Mom 40.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: MBIO -67.38% PTN -43.29% Spread: +24.09 pp (PTN Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
MBIO TTM Op. Margin: 0.0% PTN TTM Op. Margin: -65.7%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on MBIO vs PTN. Trailing 12-month operating profitability (MBIO 0.0% vs PTN -65.7%) and valuation multiples (MBIO N/M vs PTN 42.9x Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: MBIO (6) vs PTN (3)
Institutional Metric MBIO PTN Criterion Row Winner
Market Capitalization Scale $3.2M $11.1M Larger Scale Tie
Trailing P/E Ratio Valuation N/M 42.9x Lower Multiple PTN
Forward P/E Ratio Valuation N/M 42.9x Lower Multiple PTN
Revenue Growth (YoY) Growth +0.0% -80.1% Higher Growth MBIO
Operating Margin (TTM) Profitability 0.0% -65.7% Higher Margin MBIO
Net Profit Margin Profitability 0.0% -63.5% Higher Margin MBIO
Return on Equity (ROE) Capital Efficiency -43.1% -877.5% Higher ROE MBIO
52-Week Range Position Momentum 4% ($0โ€“$1) 6% ($5โ€“$31) Stronger Trend PTN
Beta / 30D Volatility Risk Regime 0.66ฮฒ ยท 86% Vol 0.87ฮฒ ยท 106% Vol Lower Realized Risk MBIO
Unified Institutional Score Composite Signal 42.9 / 100 (HOLD) 31.5 / 100 (SELL) Higher Composite MBIO

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full MBIO vs PTN Buy Guide
MBIO UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live MBIO Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
PTN UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live PTN Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither MBIO nor PTN registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.